Association between mesenchymal stem cell treatment and modulation of the ciRS-7/miR-7/Myrip/Pax6 axis in diabetes
Year: 2026
Type: article
Abstract: BACKGROUNDDiabetes mellitus is a global epidemic primarily driven by pancreatic β-cell dysfunction.Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach for diabetes, yet their underlying mechanisms remain incompletely understood.The circular RNA ciRS-7 (CDR1as) sponges miR-7, a negative regulator of β-cell function, affecting downstream targets Myrip and Pax6.However, whether MSC treatment is associated with this axis is unknown. AIMTo investigate whether MSC treatment is associated with modulation of the ciRS-7/miR-7/Myrip/Pax6 axis and with changes in β-cell function in diabetes. METHODSIn vitro, in INS-1 β-cells, ciRS-7 was silenced using specific siRNAs or overexpressed via plasmid transfection, followed by co-culture with MSCs.Cell Counting Kit-8 absorbance in the co-culture system, insulin levels in the culture supernatant (enzyme-linked immunosorbent assay), and expression of ciRS-7, miR-7, Myrip, and Pax6 (quantitative reverse transcription PCR/Western blot) were measured.In vivo, type 2 diabetes mellitus rats were treated with human umbilical cord MSCs (hUC-MSCs) or phosphate-buffered saline; blood glucose, intraperitoneal glucose tolerance test, pancreatic histology, β-cell ultrastructure, and molecular changes were evaluated. RESULTSIn vitro, MSC treatment was associated with increased total ciRS-7 in the co-culture system and insulin levels in the culture supernatant in a dose-dependent manner.ciRS-7 knockdown attenuated these MSC-associated effects, while ciRS-7 overexpression 4 / 40 enhanced them, along with reciprocal changes in miR-7, Myrip, and Pax6.In vivo, hUC-MSC treatment improved glycemic control and glucose tolerance and was associated with structural changes consistent with improved islet morphology, as well as upregulation of ciRS-7, Pax6, and Myrip and downregulation of miR-7. CONCLUSIONThese findings link MSC-based therapy to the ciRS-7/miR-7/Myrip/Pax6 axis.MSC treatment was associated with significant improvement in glycemic control and with changes in this axis.
Source: World Journal of Diabetes
DOI: 10.4239/wjd.125659
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7233746543
